register

News & Trends - MedTech & Diagnostics

Australian innovation could solve ‘urgent unmet need’ for 463 million people worldwide

Health Industry Hub | November 18, 2019 |

A world-first Australian innovation could solve an urgent unmet need for 463 million people living with diabetes worldwide.

Up to 60 per cent of people with Type 1 diabetes and 67 per cent of those with Type 2 diabetes do not monitor blood glucose as often as recommended, with ‘fear of needles and pain of finger-pricking’ as the major reasons for reduced self-monitoring of blood glucose, the paper reports.

The Australian-invented Saliva Glucose Biosensor is the world’s first non-invasive replacement for finger-prick blood glucose testing.

ISO testing has shown the Saliva Glucose Biosensor can accurately monitor glucose levels in saliva at concentrations 100 times lower than levels detected in blood by other glucose monitoring devices.

New data released by the International Diabetes Federation (IDF) for World Diabetes Day 2019 on November 14, reports that 463 million people are currently living with diabetes globally – 25 million more people than was predicted by the IDF in 2010 for the year 2025.

You may also like 91% of clinicians use reprints to improve patient care

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.


News & Trends - Pharmaceuticals

Federal court dismisses Arrotex dispute against Health Minister

Federal court dismisses Arrotex dispute against Health Minister

Health Industry Hub | July 12, 2024 |

Pharma News: The Federal Court has ruled against Arrotex Pharmaceuticals in their bid to challenge the Minister for Health and […]

More


News & Trends - Pharmaceuticals

Largest diabetes study reveals major benefits of dual therapy with SGLT2 inhibitors and GLP1 receptor agonists

Largest diabetes study reveals major benefits of SGLT2 inhibitors and GLP1 receptor agonists dual therapy

Health Industry Hub | July 12, 2024 |

Pharma News: Combined use of sodium glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP1-RAs) is likely to […]

More


News & Trends - Pharmaceuticals

Queensland opens first regional CAR T-cell treatment centre

Queensland launches first regional CAR T-cell treatment centre

Health Industry Hub | July 12, 2024 |

Pharma News: Gilead Sciences and Lymphoma Australia have welcomed the opening of Australia’s first regional CAR T-cell treatment centre at […]

More


News & Trends - Pharmaceuticals

Government inaction leaves essential medicine shortages unresolved

Government inaction leaves essential medicine shortages unresolved

Health Industry Hub | July 12, 2024 |

Pharma News: Over the past 12 months, at least six essential medications and products have been withdrawn from the Australian […]

More


This content is copyright protected. Please subscribe to gain access.